Temsirolimus Enhances Anti-Tumour Effects of Cancer Vaccines
Author Information
Author(s): Wang Y, Wang X-Y, Subjeck J R, Shrikant P A, Kim H L
Primary Institution: Cedars-Sinai Medical Center
Hypothesis
Can temsirolimus enhance the effectiveness of cancer vaccines in treating renal cell carcinoma and melanoma?
Conclusion
Temsirolimus enhances the anti-tumour immunity induced by HSP-based cancer vaccines.
Supporting Evidence
- Temsirolimus enhanced the anti-tumour activity of cancer vaccines in murine models.
- Mice treated with both temsirolimus and cancer vaccines showed greater immune responses.
- Temsirolimus increased the formation of memory CD8 T cells following vaccination.
Takeaway
Temsirolimus is a medicine that helps cancer vaccines work better by boosting the immune response against tumors.
Methodology
The study used murine models to evaluate the immune-modulating effects of temsirolimus in combination with cancer vaccines targeting renal cell carcinoma and melanoma.
Limitations
The study was conducted in murine models, which may not fully replicate human responses.
Participant Demographics
Wild-type C57BL/6 and BALB/C mice, 6–8 weeks old.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website